PRECISION BIOSCIENCES INC
NASDAQ: DTIL (Precision BioSciences, Inc.)
Last update: 5 hours ago4.45
-0.19 (-4.09%)
| Previous Close | 4.64 |
| Open | 4.60 |
| Volume | 133,259 |
| Avg. Volume (3M) | 247,155 |
| Market Cap | 49,342,488 |
| Price / Sales | 0.720 |
| Price / Book | 1.04 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -42.99% |
| Operating Margin (TTM) | -76,248.27% |
| Diluted EPS (TTM) | -2.87 |
| Quarterly Revenue Growth (YOY) | -99.80% |
| Total Debt/Equity (MRQ) | 60.30% |
| Current Ratio (MRQ) | 6.62 |
| Operating Cash Flow (TTM) | -58.52 M |
| Levered Free Cash Flow (TTM) | 6.86 M |
| Return on Assets (TTM) | -17.83% |
| Return on Equity (TTM) | -50.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Precision BioSciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | 0.63 |
|
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.07% |
| % Held by Institutions | 42.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lynx1 Capital Management Lp | 31 Mar 2025 | 766,051 |
| Aquilo Capital Management, Llc | 31 Mar 2025 | 726,149 |
| Boothbay Fund Management, Llc | 31 Mar 2025 | 200,000 |
| Tejara Capital Ltd | 31 Mar 2025 | 60,427 |
| 52 Weeks Range | ||
| Median | 60.00 (1,248.32%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 May 2025 | 60.00 (1,248.31%) | Buy | 4.65 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |